These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 10164060)

  • 1. Formulary management of ACE inhibitors.
    Gerbrandt KR; Yedinak KC
    Pharmacoeconomics; 1996 Dec; 10(6):594-613. PubMed ID: 10164060
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oral angiotensin-converting-enzyme inhibitors.
    Verme-Gibboney C
    Am J Health Syst Pharm; 1997 Dec; 54(23):2689-703. PubMed ID: 9408513
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Factors to consider in selecting an angiotensin-converting-enzyme inhibitor.
    Waugh WJ
    Am J Health Syst Pharm; 2000 Oct; 57 Suppl 1():S26-30. PubMed ID: 11030020
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lisinopril. A review of its pharmacology and clinical efficacy in elderly patients.
    Langtry HD; Markham A
    Drugs Aging; 1997 Feb; 10(2):131-66. PubMed ID: 9061270
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Angiotensin-converting enzyme inhibitors.
    Brown NJ; Vaughan DE
    Circulation; 1998 Apr; 97(14):1411-20. PubMed ID: 9577953
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Newer ACE inhibitors. A look at the future.
    Salvetti A
    Drugs; 1990 Dec; 40(6):800-28. PubMed ID: 2078997
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Angiotensin converting enzyme (ACE) inhibitors and heart failure. The consequences of underprescribing.
    Andersson F; Cline C; Rydén-Bergsten T; Erhardt L
    Pharmacoeconomics; 1999 Jun; 15(6):535-50. PubMed ID: 10538327
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of the total cost of treating elderly hypertensive patients with ACE inhibitors: a comparison of older and newer agents.
    Small RE; Freeman-Arnold SB; Goode JV; Pyles MA
    Pharmacotherapy; 1997; 17(5):1011-6. PubMed ID: 9324190
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Angiotensin converting enzyme inhibitors and moderate hypertension.
    McAreavey D; Robertson JI
    Drugs; 1990 Sep; 40(3):326-45. PubMed ID: 2226219
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical pharmacokinetics of vasodilators. Part I.
    Kirsten R; Nelson K; Kirsten D; Heintz B
    Clin Pharmacokinet; 1998 Jun; 34(6):457-82. PubMed ID: 9646008
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Renal effects of angiotensin-converting enzyme inhibitors that result in cost savings and improved patient outcomes.
    Swislocki AL; Siegel D
    Am J Manag Care; 2001 Mar; 7(3):283-95. PubMed ID: 11258145
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [ACE-inhibitors: physiologic premises and pharmacologic profiles].
    Marino A; Schettini G; Florio T; Ventra C
    Clin Ter; 1990 Feb; 132(4):267-76. PubMed ID: 2140314
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quinapril. A reappraisal of its pharmacology and therapeutic efficacy in cardiovascular disorders.
    Plosker GL; Sorkin EM
    Drugs; 1994 Aug; 48(2):227-52. PubMed ID: 7527326
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of angiotensin-converting enzyme inhibitors versus angiotensin II receptor blockers as first-line treatment in autosomal dominant polycystic kidney disease.
    Clark LA; Whitmire S; Patton S; Clark C; Blanchette CM; Howden R
    J Med Econ; 2017 Jul; 20(7):715-722. PubMed ID: 28332417
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Management of hypertension and its sequelae with ACE inhibitors: biochemical, pharmacological and clinical aspects.
    Rangoonwala B; Rosenthal I
    Int J Clin Pract; 1998 Oct; 52(7):492-500. PubMed ID: 10622092
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lisinopril. A review of its pharmacology and clinical efficacy in the early management of acute myocardial infarction.
    Goa KL; Balfour JA; Zuanetti G
    Drugs; 1996 Oct; 52(4):564-88. PubMed ID: 8891468
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The cost effectiveness of ACE inhibitors as first-line antihypertensive therapy.
    Nordmann AJ; Krahn M; Logan AG; Naglie G; Detsky AS
    Pharmacoeconomics; 2003; 21(8):573-85. PubMed ID: 12751915
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical pharmacokinetics of angiotensin converting enzyme (ACE) inhibitors in renal failure.
    Hoyer J; Schulte KL; Lenz T
    Clin Pharmacokinet; 1993 Mar; 24(3):230-54. PubMed ID: 8462229
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ACE inhibitors in elderly patients with hypertension. Special considerations.
    Ravid M; Ravid D
    Drugs Aging; 1996 Jan; 8(1):29-37. PubMed ID: 8785466
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost effectiveness of ACE inhibitor treatment for patients with type 1 diabetes mellitus.
    Dong FB; Sorensen SW; Manninen DL; Thompson TJ; Narayan V; Orians CE; Gregg EW; Eastman RC; Dasbach EJ; Herman WH; Newman JM; Narva AS; Ballard DJ; Engelgau MM
    Pharmacoeconomics; 2004; 22(15):1015-27. PubMed ID: 15449965
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.